Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adaptive Biotechnologies Corporation Announces Grand Opening of Headquarters and Expands Footprint in Seattle

09/21/2021 | 04:05pm EDT

Adaptive Biotechnologies Corporation announced the opening of its new corporate headquarters and laboratory facility located in the heart of South Lake Union – Seattle’s life sciences hub. The new headquarters, located at 1165 Eastlake Ave. East, was developed in close partnership with Alexandria Real Estate Equities Inc. and Seattle architect Ben de Rubertis of Flad Architects. The 100,086 square foot glass-enclosed laboratory and office space will make room for Adaptive’s rapidly expanding workforce and laboratory operations. Since the start of the COVID-19 pandemic, Adaptive has nearly doubled its workforce and anticipates continuing its rapid hiring trajectory. The new location contains over 20,000 square feet of laboratory space, which will allow the company to continue applying its immune medicine platform to expand its diagnostic pipeline and drug discovery partnerships. Adaptive also announced the launch of its corporate social responsibility program with STEM Paths Innovation Network (SPIN) by providing a charitable contribution for SPIN Girls Fellows, a program that prepares 11th and 12th grade girls of color in King County for college and STEM careers with the mission of closing the opportunity gap in STEM education and increasing the number of women of color in STEM fields.


© S&P Capital IQ 2021
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
10/06ADAPTIVE BIOTECHNOLOGIES : to Report Third Quarter Financial Results on November 3, 2021
AQ
10/02ADAPTIVE BIOTECHNOLOGIES : Presents New Data During IDWeek Demonstrating the Capability of..
AQ
10/02Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability o..
CI
09/30ADAPTIVE BIOTECHNOLOGIES : Launches Enhanced clonoSEQ® Assay Reports for Patients with Chr..
AQ
09/30Adaptive Biotechnologies Corporation Launches Enhanced clonoSEQ® Assay Reports for Pati..
CI
09/22ADAPTIVE BIOTECHNOLOGIES : Investor Presentation - June 2021
PU
09/21Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and E..
GL
09/21Adaptive Biotechnologies Corporation Announces Grand Opening of Headquarters and Expand..
CI
09/16ADAPTIVE BIOTECHNOLOGIES : to Present New SARS-CoV-2 Data from its Immune Medicine Platfor..
AQ
09/16Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platfo..
CI
More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Financials (USD)
Sales 2021 153 M - -
Net income 2021 -216 M - -
Net cash 2021 362 M - -
P/E ratio 2021 -22,2x
Yield 2021 -
Capitalization 4 735 M 4 735 M -
EV / Sales 2021 28,6x
EV / Sales 2022 21,8x
Nbr of Employees 622
Free-Float 98,4%
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 33,64 $
Average target price 56,67 $
Spread / Average Target 68,5%
EPS Revisions
Managers and Directors
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen Chief Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors